The Form 4 filing was submitted on November 17, 2026, for trades dated November 13, 2026. Form 4 is the SEC report used to disclose an insider's stock trades. It names James N. Wilson as a Corcept Therapeutics director.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-13 |
| Buy/Sell | sell |
| Transaction Count | 4 |
| Shares Transacted | 10,000 |
| Price | $72.67 |
| Total Transaction Value | $726,677.94 |
| Insider | |
| Ticker Symbol | CORT |
| Company | CORCEPT THERAPEUTICS INC |
| Insider Name | WILSON JAMES N |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 1,044,543 |
| Position Size Change | 0.95% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of CORT shares, reported under transaction code S. One filing covers the four sale transactions by one insider.
What was the average price of the transaction?
The average sale price was $72.67 per share, rounded to the nearest cent. This figure covers all four sales. Prices for each separate sale are not available.
How did this transaction affect the insider's holdings?
James N. Wilson sold 10,000 shares and reported 1,044,543 shares owned afterward. The shares sold made up about 0.95% of his reported shares owned before the sales. The reported balance therefore shows that he retained shares after these trades.
What's the total transaction value?
The total value was $726,677.94 for all four sales. This rounds the recorded value of $726,677.9383 to the nearest cent.
Are there any special circumstances around this transaction?
The available information points to a Rule 10b5-1 trading plan. Such plans set instructions in advance for future stock trades. Footnote text is unavailable, so it is unclear which of the four sales the plan covered. Its start date and trading schedule are also unknown.
For research purposes only; not investment advice.